News

The Dose Podcast: Ep 1 "TB and the AMR Crisis"

The Stop TB Partnership's Working Group on New Drugs presents a new podcast series entitled "The Dose". In this series, the WGND will bring together drug developers, researchers in the TB R&D field, TB patients, global health experts, and donors to discuss, prioritize, and develop strategies to help meet the most pressing needs faced by the TB drug R&D community.

Episode 1 "TB and the AMR Crisis"

Episode 1 will focus on TB and antimicrobial resistance (AMR). Today, AMR is one of the defining health issues of our time. Drug resistant tuberculosis is the cornerstone of the global AMR challenge, which accounts for a quarter of AMR fatalities per year. This podcast will highlight the opportunities, and challenges to advancing action on AMR and tuberculosis.

Moderator: Shobha Shukla, Citizen News Service

Speaker: Mario Raviglione, University of Milan (Previously Global TB Programme, WHO) 

Speaker: Manica Balasegaram, Global Antibiotic Research and Develpment Partnership (GARDP)

 

Listen on Soundcloud: https://soundcloud.com/user-87209407/the-dose-podcast-july-2018 

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...